AIM
Price
$0.44
Change
-$0.00 (-0.00%)
Updated
Mar 27, 6:59 PM EST
5 days until earnings call
SVRA
Price
$4.85
Change
-$0.00 (-0.00%)
Updated
Mar 27, 2:59 PM EST
42 days until earnings call
Ad is loading...

Analysis and predictions AIM vs SVRA

Header iconAIM vs SVRA Comparison
Open Charts AIM vs SVRABanner chart's image
AIM ImmunoTech
Price$0.44
Change-$0.00 (-0.00%)
Volume$90.97K
CapitalizationN/A
Savara
Price$4.85
Change-$0.00 (-0.00%)
Volume$6.95K
CapitalizationN/A
View a ticker or compare two or three
AIM vs SVRA Comparison Chart

Loading...

AIMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SVRADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AIM vs. SVRA commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and SVRA is a StrongSell.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (AIM: $0.44 vs. SVRA: $4.85)
Brand notoriety: AIM and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 82% vs. SVRA: 37%
Market capitalization -- AIM: $21.64M vs. SVRA: $670.02M
AIM [@Biotechnology] is valued at $21.64M. SVRA’s [@Biotechnology] market capitalization is $670.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • AIM’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, AIM is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 5 TA indicator(s) are bullish while SVRA’s TA Score has 2 bullish TA indicator(s).

  • AIM’s TA Score: 5 bullish, 4 bearish.
  • SVRA’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, AIM is a better buy in the short-term than SVRA.

Price Growth

AIM (@Biotechnology) experienced а +10.72% price change this week, while SVRA (@Biotechnology) price change was -0.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.41%. For the same industry, the average monthly price growth was +5.97%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

AIM is expected to report earnings on May 16, 2024.

SVRA is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+4.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AIM with price predictions.
OPEN
A.I.dvisor published
a Summary for SVRA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SVRA($670M) has a higher market cap than AIM($21.6M). SVRA YTD gains are higher at: 3.191 vs. AIM (0.705). AIM has higher annual earnings (EBITDA): -22.64M vs. SVRA (-59.04M). SVRA has more cash in the bank: 162M vs. AIM (22.4M). AIM has less debt than SVRA: AIM (750K) vs SVRA (26.5M). AIM has higher revenues than SVRA: AIM (193K) vs SVRA (0).
AIMSVRAAIM / SVRA
Capitalization21.6M670M3%
EBITDA-22.64M-59.04M38%
Gain YTD0.7053.19122%
P/E RatioN/AN/A-
Revenue193K0-
Total Cash22.4M162M14%
Total Debt750K26.5M3%
FUNDAMENTALS RATINGS
AIM vs SVRA: Fundamental Ratings
AIM
SVRA
OUTLOOK RATING
1..100
5612
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5441
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AIM's Valuation (47) in the null industry is in the same range as SVRA (74) in the Biotechnology industry. This means that AIM’s stock grew similarly to SVRA’s over the last 12 months.

AIM's Profit vs Risk Rating (100) in the null industry is in the same range as SVRA (100) in the Biotechnology industry. This means that AIM’s stock grew similarly to SVRA’s over the last 12 months.

AIM's SMR Rating (97) in the null industry is in the same range as SVRA (97) in the Biotechnology industry. This means that AIM’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Price Growth Rating (41) in the Biotechnology industry is in the same range as AIM (54) in the null industry. This means that SVRA’s stock grew similarly to AIM’s over the last 12 months.

SVRA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that SVRA’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMSVRA
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 15 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
AIMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SVRADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PASSX59.991.06
+1.80%
T. Rowe Price Small-Cap Stock Adv
WIMVX11.050.07
+0.64%
Segall Bryant & Hamill Glb All Cp Inst
MDDRX12.18N/A
N/A
MassMutual Diversified Value R4
MTCAX60.71N/A
N/A
MFS Technology A
NEAIX49.95N/A
N/A
Needham Aggressive Growth Institutional

AIM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AIM has been loosely correlated with HOTH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then HOTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+0.91%
HOTH - AIM
33%
Loosely correlated
-8.72%
SLDB - AIM
26%
Poorly correlated
+5.01%
AVRO - AIM
25%
Poorly correlated
N/A
SEEL - AIM
25%
Poorly correlated
+15.87%
VRCA - AIM
24%
Poorly correlated
+6.20%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with CBAY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then CBAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-1.22%
CBAY - SVRA
35%
Loosely correlated
N/A
FOLD - SVRA
35%
Loosely correlated
+3.85%
DYN - SVRA
33%
Loosely correlated
+6.42%
AGIO - SVRA
33%
Poorly correlated
+0.34%
GERN - SVRA
32%
Poorly correlated
+0.91%
More